Castle Biosciences' Total Liabilities rose 3024.08% to $95.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.7 million, marking a year-over-year increase of 3024.08%. This contributed to the annual value of $75.4 million for FY2024, which is 2147.38% up from last year.
Per Castle Biosciences' latest filing, its Total Liabilities stood at $95.7 million for Q3 2025, which was up 3024.08% from $89.4 million recorded in Q2 2025.
Over the past 5 years, Castle Biosciences' Total Liabilities peaked at $95.7 million during Q3 2025, and registered a low of $18.7 million during Q1 2021.
Its 5-year average for Total Liabilities is $52.9 million, with a median of $50.2 million in 2023.
In the last 5 years, Castle Biosciences' Total Liabilities crashed by 5533.88% in 2021 and then skyrocketed by 15120.83% in 2022.
Castle Biosciences' Total Liabilities (Quarter) stood at $50.8 million in 2021, then dropped by 5.22% to $48.2 million in 2022, then grew by 28.83% to $62.1 million in 2023, then grew by 21.47% to $75.4 million in 2024, then rose by 26.98% to $95.7 million in 2025.
Its Total Liabilities stands at $95.7 million for Q3 2025, versus $89.4 million for Q2 2025 and $61.4 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value